Loading…
Drugs Made In America Acquisition Corp. is projected to rise to $12.19 by 2027, a +15% move from its current price of $10.60. DMAA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $10.57 | $10.60 | $10.63 | -0.02% |
| May 30 | $10.56 | $10.60 | $10.64 | -0.03% |
| May 31 | $10.55 | $10.60 | $10.64 | -0.05% |
| Jun 1 | $10.54 | $10.59 | $10.65 | -0.06% |
| Jun 2 | $10.53 | $10.59 | $10.65 | -0.08% |
| Jun 3 | $10.52 | $10.59 | $10.66 | -0.09% |
| Jun 4 | $10.52 | $10.59 | $10.66 | -0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.52 | $10.59 | $10.66 | -0.11% |
| Week 2 | $10.47 | $10.58 | $10.68 | -0.21% |
| Week 3 | $10.44 | $10.57 | $10.69 | -0.32% |
| Week 4 | $10.41 | $10.55 | $10.70 | -0.43% |
| Week 5 | $10.38 | $10.54 | $10.71 | -0.53% |
| Week 6 | $10.36 | $10.53 | $10.71 | -0.64% |
| Week 7 | $10.33 | $10.52 | $10.72 | -0.75% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Drugs Made In America Acquisition Corp. (DMAA) is described as a financial services company with limited ongoing operations. It was incorporated in 2024 and is based in New York, New York.
The company states its plan to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. It trades under the symbol DMAA.
DMAA is currently priced at $10.60 per share and has a market capitalization of $257.34M. It is ranked 3646 by market cap.
The near-term price picture shows constructive momentum, with a 30-day range of $10.53 to $10.67, a bullish technical backdrop, and key levels of support at $10.52 and resistance at $10.60. The 30-day snapshot also highlights RSI14 of 60, with SMA50 at $10.54 and SMA200 at $10.39.
Looking further out, the multi-year forecast points to meaningful upside. The avg price rises from $10.60 in 2026 to $97.19 in 2050, with max forecasts up to $165.77 and ROIs expanding from 0% to 816.9% over the period. This suggests a positive long-term trajectory, but these figures are estimates, not guarantees, and depend on a range of market factors.
A major floor 1.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.7% away) — a key level to hold.
Price is pressing into resistance (0.1% away) — a breakout level to watch.
A major ceiling 0.6% above — clearing it would confirm fresh momentum.
Key DMAA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DMAA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.60 | Sell | $10.60 | Sell |
| MA 10 | $10.60 | Buy | $10.60 | Buy |
| MA 20 | $10.59 | Buy | $10.59 | Buy |
| MA 50 | $10.54 | Buy | $10.55 | Buy |
| MA 100 | $10.49 | Buy | $10.50 | Buy |
| MA 200 | $10.40 | Buy | $10.41 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.51 | Neutral |
| Stoch RSI (14) | 28.11 | Neutral |
| CCI (20) | 54.87 | Neutral |
| Williams %R (14) | -33.33 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 0.00 | Neutral |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 66.67 | Neutral |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 57.50 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 10.61 | Sell |
| ADX (14) | 28.59 | Buy |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is bullish overall.
RSI(14) is 60, and the 50-day simple moving average stands at $10.54 while the 200-day simple moving average sits at $10.39. Immediate support is at $10.52 and resistance at $10.60. The 30-day price range runs from $10.53 to $10.67, indicating a tight, potentially directional trading window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.37 | $10.60 | $14.06 | 0% | Neutral | |
| $9.86 | $12.19 | $15.82 | +15% | Neutral | |
| $11.63 | $14.67 | $19.60 | +38% | Bullish | |
| $13.93 | $17.87 | $24.44 | +69% | Bullish | |
| $15.58 | $20.30 | $28.32 | +92% | Bullish | |
| $16.17 | $21.36 | $30.31 | +102% | Bullish | |
| $17.20 | $23.02 | $33.18 | +117% | Bullish | |
| $18.52 | $25.09 | $36.67 | +137% | Bullish | |
| $18.72 | $25.65 | $37.99 | +142% | Bullish | |
| $21.59 | $29.92 | $44.85 | +182% | Bullish | |
| $29.06 | $42.30 | $66.75 | +299% | Bullish | |
| $61.48 | $97.20 | $165.51 | +817% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $10.37 | $10.60 | $12.42 | +0.00% |
| June 2026 | $8.95 | $10.46 | $12.48 | -1.30% |
| July 2026 | $8.88 | $10.45 | $12.61 | -0.09% |
| August 2026 | $9.17 | $10.84 | $13.19 | +3.74% |
| September 2026 | $9.27 | $11.01 | $13.48 | +1.55% |
| October 2026 | $9.11 | $10.87 | $13.38 | -1.32% |
| November 2026 | $9.20 | $11.00 | $13.63 | +1.26% |
| December 2026 | $9.41 | $11.30 | $14.06 | +2.67% |
Click any year to see its month-by-month DMAA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, DMAA is projected to trade between $10.37 and $14.06, averaging $10.60 — a potential gain of 0% from today's $10.60. Price action looks broadly range-bound.
Drugs Made In America Acquisition Corp.'s 2027 outlook centres on $12.19, within a $9.86 to $15.82 range. That is up +15% on the projected 2026 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, DMAA could reach as high as $19.60, with a base case around $14.67 and support toward $11.63 — roughly +38% from $10.60. Momentum favours further upside here.
Expect DMAA to range from $13.93 to $24.44 through 2029. The $17.87 average target implies a +69% move from current prices. That is up +22% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The DMAA price prediction for 2030 points to an average of $20.30 (low $15.58, high $28.32) — a potential gain of +92% on today's $10.60. Momentum favours further upside here.
In 2031, DMAA is projected to trade between $16.17 and $30.31, averaging $21.36 — a potential gain of +102% from today's $10.60. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Drugs Made In America Acquisition Corp.'s 2032 outlook centres on $23.02, within a $17.20 to $33.18 range. That is up +8% on the projected 2031 average. That marks a +117% change versus current levels. Momentum favours further upside here.
By 2033, DMAA could reach as high as $36.67, with a base case around $25.09 and support toward $18.52 — roughly +137% from $10.60. Buyers look set to stay in control over this stretch.
Expect DMAA to range from $18.72 to $37.99 through 2034. The $25.65 average target implies a +142% move from current prices. That is up +2% on the projected 2033 average. Momentum favours further upside here.
The DMAA price prediction for 2035 points to an average of $29.92 (low $21.59, high $44.85) — a potential gain of +182% on today's $10.60. Buyers look set to stay in control over this stretch.
In 2040, DMAA is projected to trade between $29.06 and $66.75, averaging $42.30 — a potential gain of +299% from today's $10.60. That is up +41% on the projected 2035 average. Momentum favours further upside here.
Drugs Made In America Acquisition Corp.'s 2050 outlook centres on $97.20, within a $61.48 to $165.51 range. That is up +130% on the projected 2040 average. That marks a +817% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in DMAA today (≈ 94.339623 DMAA) could be worth
$9,169.55
+$8,169.55 (+817%) by 2050 · US Dollar
Based on the average projected DMAA price of $97.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DMAAwould be worth at today's price.
$1,000 invested in DMAA on May 27, 2025 (≈ 98.81423 DMAA) would be worth
$1,047.43
+$47.43 (+4.7%) today · 1.05× · US Dollar
Based on a DMAA entry price of $10.12 vs. today's $10.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.59 | $1,000.94 | +0.1% |
| 1 month ago | $10.56 | $1,003.31 | +0.3% |
| 3 months ago | $10.48 | $1,011.45 | +1.1% |
| 6 months ago | $10.33 | $1,026.14 | +2.6% |
| 1 year ago | $10.12 | $1,047.43 | +4.7% |
| All time (1.2y) ago | $9.96 | $1,064.26 | +6.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DMAA forecast.
Our base-case forecast reaches $21.00 around 2031.
Implied market cap at $21.00: $509.82M
Over the multi-year horizon, the forecast highlights substantial upside, with the average price climbing to $20.22 by 2030 (ROI 90.7%) and continuing higher to $42.55 by 2040 (ROI 301.4%), then to $97.19 by 2050 (ROI 816.9%). In 2027 the avg is $12.14 (ROI 14.5%), in 2028 $14.79 (ROI 39.6%), and in 2029 $17.92 (ROI 69.1%). These figures illustrate a long-run upward trajectory with bullish sentiment in later years, though they come with uncertainty and are not guarantees.
The forecast also shows progressively higher baselines beyond 2030, reinforcing a growth outlook while acknowledging the inherent risk of market shifts and execution outcomes.
Tap a question to reveal the answer.
In 2030 the avg forecast is $20.22 with a min of $15.50 and a max of $28.22, and the ROI is 90.7%. The sentiment for that year is bullish.
The long-range forecast shows multiple years with bullish sentiment and rising averages, including a 2030 avg of $20.22 and a 2050 avg of $97.19 with an 816.9% ROI. However, these are estimates and not guarantees; investing involves risk.
The forecast max for 2050 is $165.77 and the avg is $97.19, so crossing the $100 level is within the forecast range, albeit not guaranteed.
The current price is $10.60 and the market capitalization is $257.34M.
For 2027, the avg forecast is $12.14, with a min of $9.82 and a max of $15.78. The ROI is 14.5% and the sentiment is neutral.
Drugs Made In America Acquisition Corp. Community Discussion
0Share your Drugs Made In America Acquisition Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.